GeoVax Labs, Inc. (GOVX)
NASDAQ: GOVX · Real-Time Price · USD
0.7247
+0.0435 (6.39%)
At close: Aug 3, 2026, 4:00 PM EDT
0.7010
-0.0237 (-3.27%)
Pre-market: Aug 4, 2026, 7:16 AM EDT
GeoVax Labs Revenue
In the year 2025, GeoVax Labs had annual revenue of $2.49M, down -37.06%.
Revenue (ttm)
$2.49M
Revenue Growth
-37.06%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
5.34M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.49M | -1.47M | -37.06% |
| Dec 31, 2024 | 3.95M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 81.53K | -303.98K | -78.85% |
| Dec 31, 2021 | 385.50K | -1.44M | -78.86% |
| Dec 31, 2020 | 1.82M | 647.76K | 55.09% |
| Dec 31, 2019 | 1.18M | 212.69K | 22.08% |
| Dec 31, 2018 | 963.20K | -112.07K | -10.42% |
| Dec 31, 2017 | 1.08M | 246.35K | 29.72% |
| Dec 31, 2016 | 828.92K | 400.84K | 93.64% |
| Dec 31, 2015 | 428.08K | -454.88K | -51.52% |
| Dec 31, 2014 | 882.96K | -1.53M | -63.48% |
| Dec 31, 2013 | 2.42M | -239.78K | -9.02% |
| Dec 31, 2012 | 2.66M | -2.24M | -45.77% |
| Dec 31, 2011 | 4.90M | -285.37K | -5.50% |
| Dec 31, 2010 | 5.19M | 1.52M | 41.36% |
| Dec 31, 2009 | 3.67M | 758.03K | 26.05% |
| Dec 31, 2008 | 2.91M | 2.67M | 1,127.90% |
| Dec 31, 2007 | 237.00K | -615.90K | -72.21% |
| Dec 31, 2006 | 852.91K | 182.44K | 27.21% |
| Dec 31, 2005 | 670.47K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioAtla | 2.00M |
| Evogene | 1.84M |
| Bio Green Med Solution | 1.53M |
| CollPlant Biotechnologies | 389.00K |
| BioRestorative Therapies | 357.87K |
| Cardio Diagnostics Holdings | 16.57K |
GOVX News
- 7 days ago - GeoVax Labs Earnings release: Q2 2026 - Filings
- 7 days ago - GeoVax Labs Quarterly report: Q2 2026 - Filings
- 13 days ago - GeoVax Labs Slides: Corporate presentation - Filings
- 2 months ago - GeoVax Labs Transcript: Investor update - Transcripts
- 2 months ago - GeoVax Labs discontinues development of COVID-19 vaccine candidate - TheFly
- 2 months ago - Roth Capital ‘strongly’ agrees with GeoVax ending COVID-19 development - TheFly
- 2 months ago - GeoVax Labs files to sell 7.64M shares of common stock for holders - TheFly
- 2 months ago - GeoVax Labs Registration statement: Registration filing - Filings